Stay updated on Atezolizumab Subq in NSCLC: Clinical Trial

Sign up to get notified when there's something new on the Atezolizumab Subq in NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Atezolizumab Subq in NSCLC: Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added, and the previous notices about government funding lapses and NIH operating status were removed. These are administrative site updates and do not change the study details or functionality presented on the page.
    Difference
    0.2%
    Check dated 2026-02-11T14:26:40.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a government funding lapse notice at the top of the page with guidance and links to cc.nih.gov and opm.gov, and updated the revision tag from v3.4.0 to v3.4.1.
    Difference
    0.2%
    Check dated 2026-02-04T10:40:42.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Show glossary added to the page. The QC-related labels were updated to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and the revision version was bumped to v3.4.0 from v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-28T06:22:09.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page shows a minor revision update from v3.3.3 to v3.3.4; no observable changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:43:43.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Locations section expanded with additional regional locations (e.g., Rio Grande do Sul, São Paulo, Lombardy, Mexico City, Querétaro, Moscow Oblast, Niznij Novgorod, Respublika Mordoviya, Katerynoslav Governorate, Kharkiv Governorate) and a revision tag updated to v3.3.3. The older location groupings appear to have been replaced or reorganized.
    Difference
    0.7%
    Check dated 2025-12-23T21:07:12.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    Expanded the study's location list to 74 sites worldwide, adding new sites such as Ivano-Frankivsk Regional Oncology Center (Ukraine), Kaluga (Russia), Hospital Nossa Senhora da Conceicao (Brazil), ICESP (São Paulo, Brazil), Instituto do Cancer do Estado de Sao Paulo and others across Argentina, Chile, China, Mexico, Greece, New Zealand, Italy, and more. Several previously listed sites were removed.
    Difference
    3%
    Check dated 2025-12-09T15:24:05.000Z thumbnail image

Stay in the know with updates to Atezolizumab Subq in NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Atezolizumab Subq in NSCLC: Clinical Trial page.